Form 4: Serina Therapeutics Chief Scientific Officer Sells Shares Following Option Exercise
Insider Transaction Report
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned transaction, exercising stock options and subsequently selling 6,500 shares of common stock.
Summary
- Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), reported a transaction on June 30, 2025, under a Rule 10b5-1(c) plan.
- The transaction involved the exercise of 6,500 stock options at an exercise price of $0.06 per share.
- Concurrently, 6,500 shares of common stock were disposed of through sales at a weighted average price of $5.78 per share.
- The shares were sold in multiple transactions with prices ranging from $5.68 to $6.05.
- Following these transactions, Randall Moreadith's direct beneficial ownership of common stock is 0 shares, while direct beneficial ownership of derivative securities (stock options) is 514,686.
Sentiment
Score: 5
Explanation: A Form 4 is a factual disclosure of an insider transaction. While the sale of shares by an insider can be interpreted in various ways by the market, the document itself is neutral in tone and reports a routine transaction under a pre-arranged plan.
Positives
- The transaction allowed the Chief Scientific Officer to realize value from vested stock options.
- The transaction was executed under a Rule 10b5-1(c) plan, indicating it was pre-arranged and not based on immediate insider information.
Negatives
- The sale of shares by a Chief Scientific Officer could be interpreted by some investors as a signal of reduced confidence in the company's near-term prospects, despite being a pre-planned transaction.
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal, potentially influencing their perception of the company's stock value, although the transaction was pre-planned under Rule 10b5-1(c).
Key Dates
| Date | Description |
|---|---|
| 05/06/2031 | Expiration date of the stock options. |
| 06/30/2025 | Date of earliest transaction, involving both the exercise of stock options and the sale of common stock. |
| 07/02/2025 | Date the Form 4 was signed by Randall Moreadith. |
Keywords
Serina Therapeutics, SER, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.